These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 3108671)
21. Patent office decision puts Genentech out in front. Ezzell C Nature; 1987 Nov 12-18; 330(6144):97. PubMed ID: 3478596 [No Abstract] [Full Text] [Related]
22. Living organisms in patent law. Hill MM Lancet; 1970 Nov; 2(7680):986-7. PubMed ID: 4097635 [No Abstract] [Full Text] [Related]
23. Wellcome versus Genentech result. Johnston K Nature; 1987 Jul 16-22; 328(6127):189. PubMed ID: 3110626 [No Abstract] [Full Text] [Related]
24. Growing strong. Biotechnology's new wave hopes that being first will pay off. Erickson D Sci Am; 1992 Jan; 266(1):134, 136. PubMed ID: 1734508 [No Abstract] [Full Text] [Related]
25. A refined kinetic analysis of plasminogen activation by recombinant bovine tissue-type plasminogen activator indicates two interconvertible activator forms. Johnsen LB; Ravn P; Berglund L; Petersen TE; Rasmussen LK; Heegaard CW; Rasmussen JT; Benfeldt C; Fedosov SN Biochemistry; 1998 Sep; 37(36):12631-9. PubMed ID: 9730836 [TBL] [Abstract][Full Text] [Related]
31. Profile - Robert Jackson interviewed by Suzanne Berry. Jackson R Trends Biotechnol; 2002 Nov; 20(11):485-6. PubMed ID: 12413824 [No Abstract] [Full Text] [Related]
32. Patent protection upheld in Amgen/Genetics Institute battle over EPO. Riley J; Pristave R Nephrol News Issues; 1991 Apr; 5(4):18-9. PubMed ID: 1961279 [No Abstract] [Full Text] [Related]
33. Affymetrix loses first round of patent battle. Dickson D Nature; 2000 Apr; 404(6779):697. PubMed ID: 10783861 [No Abstract] [Full Text] [Related]
36. Tissue-type plasminogen activator deficiency delays bone repair: roles of osteoblastic proliferation and vascular endothelial growth factor. Kawao N; Tamura Y; Okumoto K; Yano M; Okada K; Matsuo O; Kaji H Am J Physiol Endocrinol Metab; 2014 Aug; 307(3):E278-88. PubMed ID: 24918201 [TBL] [Abstract][Full Text] [Related]
37. Quality control of rDNA-derived human tissue-type plasminogen activator. Jones AJ; Garnick RL Bioprocess Technol; 1990; 10():543-66. PubMed ID: 1367501 [No Abstract] [Full Text] [Related]
38. A partial summary of university-industry relationships in the United States. Zinder ND; Winn J Recomb DNA Tech Bull; 1984 Mar; 7(1):8-19. PubMed ID: 6587447 [No Abstract] [Full Text] [Related]
39. Patent. Battle lines are drawn over generic AIDS drug. AIDS Policy Law; 2005 Aug; 20(16):6. PubMed ID: 16161208 [No Abstract] [Full Text] [Related]
40. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis. van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]